N-(2-吡啶-4-基-乙基)-乙酰胺 | 70922-39-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(2-吡啶-4-基-乙基)-乙酰胺
• 英文名称: 4-(β-N-acetylaminoethyl)pyridine
• 英文别名: N-(2-[4]pyridyl-ethyl)-acetamide；N-(2-[4]Pyridyl-aethyl)-acetamid；4-(2-Acetamidoethyl)pyridine；4-(2-Acetamidoethyl)pyridin；N-(2-Pyridin-4-yl-ethyl)-acetamide；N-(2-pyridin-4-ylethyl)acetamide
• CAS: 70922-39-3
• 化学式: C₉H₁₂N₂O
• mdl: MFCD05257247
• 分子量: 164.207
• InChiKey: BXRBTKQGLYOOKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  N-(2-吡啶-4-基-乙基)-乙酰胺 在 sodium tetrahydroborate 、 chloroamine-T 、 碳酸氢钠 、 sodium iodide 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 1-(E-1-iodo-1-penten-5-yl)-4-(β-N-acetylaminoethyl)-1,4-dihydropyridine
  参考文献：
  名称：

  Srivastava, Prem C.; Knapp, Furn F.; Pruitt, Carol D., Journal of Heterocyclic Chemistry, 1988, vol. 25, # 2, p. 667 - 669

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(2-氨基乙基)吡啶 、 乙酸酐 反应 1.0h， 以58%的产率得到N-(2-吡啶-4-基-乙基)-乙酰胺
  参考文献：
  名称：

  Srivastava, Prem C.; Knapp, Furn F.; Pruitt, Carol D., Journal of Heterocyclic Chemistry, 1988, vol. 25, # 2, p. 667 - 669

  摘要：

  DOI：

文献信息

• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• Pteridinone derivatives as PI3-kinases inhibitors
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：EP1953163A1

  公开（公告）日：2008-08-06

  New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

  根据其作为PI3-激酶调节剂的药理活性，提供了公式1的新化合物，可用于治疗炎症或过敏性疾病的治疗领域。 这些例子包括炎症和过敏性呼吸道疾病，胃肠道和运动器官的炎症性疾病，炎症性和过敏性皮肤疾病，炎症性眼病，鼻黏膜疾病，涉及自身免疫反应或肾脏炎症的炎症性或过敏性疾病。
• COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT
  申请人：Lee Jung Joon

  公开号：US20090306078A1

  公开（公告）日：2009-12-10

  Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.

  本文披露了一种HIF-1抑制剂，其制备方法，以及包含其作为活性成分的药物组合物。该HIF-1抑制剂显示抗癌活性，这归功于其对HIF-1的抑制活性，HIF-1是一种在癌症生长和转移中起重要作用的转录因子，但不具有一般细胞毒性。因此，HIF抑制剂及其药用可接受的盐可用作治疗各种癌症，如肝癌、胃癌和乳腺癌的治疗药物。此外，具有对HIF-1抑制活性的化合物在治疗由HIF-1介导的VEGF表达加重的糖尿病视网膜病变和关节炎方面是有用的。
• Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
  申请人：Pfizer Inc.

  公开号：US04370328A1

  公开（公告）日：1983-01-25

  1-(3- or 4-substituted piperidino)phthalazines of the formula ##STR1## wherein R is C.sub.1-6 alkyl; Y is a 3- or 4-position substituent and is --X-(CHR.sup.1).sub.m -Z wherein R.sup.1 is hydrogen or C.sub.1-6 alkyl; m is 1 or 2; X is oxygen or a direct link provided that when m is 1, X is a direct link; and Z is --N(R.sup.2)COR.sup.3, --N(R.sup.2)COOR.sup.3, --N(R.sup.2)SO.sub.2 R.sup.3, --N(R.sup.2)SO.sub.2 NR.sup.4 R.sup.5, --N(R.sup.2)SOR.sup.3, --N(R.sup.2)CONR.sup.4 R.sup.5 or --OCONR.sup.4 R.sup.5, wherein R.sup.2 and R.sup.5 are each independently hydrogen or C.sub.1-6 alkyl; R.sup.3 is C.sub.1-6 alkyl, phenethyl, benzyl, C.sub.3-7 cycloalkyl, phenyl or pyridyl; R.sup.4 is hydrogen or R.sup.3 ; provided that when X is a direct link, R.sup.3 or R.sup.4 is C.sub.3-7 cycloalkyl; the pharmaceutically acceptable acid addition salts thereof; processes for their preparation; and their use as cardiac stimulants and phosphodiesterase inhibitors.

  1-(3-或4-取代哌啶基)邻苯二嗪的结构式为##STR1##其中R为C.sub.1-6烷基；Y为3-或4-位取代基，为--X-(CHR.sup.1).sub.m -Z，其中R.sup.1为氢或C.sub.1-6烷基；m为1或2；X为氧或直链，但当m为1时，X为直链；Z为--N(R.sup.2)COR.sup.3，--N(R.sup.2)COOR.sup.3，--N(R.sup.2)SO.sub.2 R.sup.3，--N(R.sup.2)SO.sub.2 NR.sup.4 R.sup.5，--N(R.sup.2)SOR.sup.3，--N(R.sup.2)CONR.sup.4 R.sup.5或--OCONR.sup.4 R.sup.5，其中R.sup.2和R.sup.5各自独立地为氢或C.sub.1-6烷基；R.sup.3为C.sub.1-6烷基，苯乙基，苄基，C.sub.3-7环烷基，苯基或吡啶基；R.sup.4为氢或R.sup.3；但当X为直链时，R.sup.3或R.sup.4为C.sub.3-7环烷基；其药学上可接受的酸盐；其制备方法；以及它们作为心脏刺激剂和磷酸二酯酶抑制剂的用途。
• [EN] PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF<br/>[FR] PYRROLO [2, 3-B] PYRIDINES OU PYRROLO [2, 3-B] PYRAZINES COMME INHIBITEUR DE HPK1 ET LEUR UTILISATION
  申请人：BEIGENE LTD

  公开号：WO2019238067A1

  公开（公告）日：2019-12-19

  Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

  本文披露了一种公式（AIII）或（III）的化合物，或其立体异构体，或其药用可接受的盐，以及包含该化合物的药物组合物。还披露了一种利用本文披露的化合物治疗HPK1相关疾病或疾病的方法。